Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates

References

• Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006;66:11520–39.
   PubMed Web of Science ®Google Scholar
• Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 2001;60: 155–61.
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate. Anticancer Res 1999;19:189–95.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R. Combination of vascular targeting agents with thermal or radiation therapy. Int J Radiat Oncol Biol Phys 2002;54:1518–23.
   PubMed Web of Science ®Google Scholar
• Landuyt W, Verdoes O, Darius DO, Drijkoningen M, Nuyts S, Theys J, . Vascular targeting of solid tumours: A major ‘inverse’ volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer 2000;36:1833–43.
   PubMed Web of Science ®Google Scholar
• Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys 2005;62:846–53.
   PubMed Web of Science ®Google Scholar
• Parkins CS, Holder AL, Hill SA, Chaplin DJ, Tozer GM. Determinants of anti-vascular action by combretastatin A-4 phosphate: Role of nitric oxide. Br J Cancer 2000;83: 811–6.
   PubMed Web of Science ®Google Scholar
• Skliarenko JV, Lunt SJ, Gordon ML, Vitkin A, Milosevic M, Hill RP. Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors. Cancer Res 2006;66:2074–80.
   PubMed Web of Science ®Google Scholar
• Ferretti S, Allegrini PR, O'Reilly T, Schnell C, Stumm M, Wartmann M, . Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res 2005;11:7773–84.
   PubMed Web of Science ®Google Scholar
• Beauregard DA, Hill SA, Chaplin DJ, Brindle KM. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 2001;61:6811–5.
   PubMed Web of Science ®Google Scholar
• Hori K, Saito S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 2003;89:1334–44.
   PubMed Web of Science ®Google Scholar
• Ferrero E, Villa A, Ferrero ME, Toninelli E, Bender JR, Pardi R, . Tumor necrosis factor alpha-induced vascular leakage involves PECAM1 phosphorylation. Cancer Res 1996;56:3211–5.
   PubMed Web of Science ®Google Scholar
• Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, . Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: Intravital microscopy and measurement of vascular permeability. Cancer Res 2001;61:6413–22.
   PubMed Web of Science ®Google Scholar
• Kim JH, Lew YS, Kolozsvary A, Ryu S, Brown SL. Arsenic trioxide enhances radiation response of 9L glioma in the rat brain. Radiat Res 2003;160:662–6.
   PubMed Web of Science ®Google Scholar
• Robinson SP, McIntyre DJO, Checkley D, Tessier JJ, Howe FA, Griffiths JR, . Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 2003;88:1592–7.
   PubMed Web of Science ®Google Scholar
• Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, . Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004;10: 3650–7.
   PubMed Web of Science ®Google Scholar
• Zhao D, Jiang L, Hahn EW, Mason RP. Tumor physiologic response to combretastatin A4 phosphate assessed by MRI. Int J Radiat Oncol Biol Phys 2005;62:872–80.
   PubMed Web of Science ®Google Scholar
• Chen G, Horsman MR, Pedersen M, Pang Q, Stødkilde-Jørgensen H. The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours. Acta Oncol 2008;47:1071–6.
   PubMed Web of Science ®Google Scholar
• Nielsen T, Murata R, Maxwell RJ, Stødkilde-Jørgensen H, Ostergaard L, Horsman MR. Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients. Int J Radiat Oncol Biol Phys 2008;70:859–66.
   PubMed Web of Science ®Google Scholar
• Nielsen T, Mouridsen K, Maxwell RJ, Stødkilde-Jørgensen H, Østergaard L, Horsman MR. Segmentation of dynamic contrast enhanced magnetic resonance imaging data. Acta Oncol 2008;47:1265–70.
   PubMed Web of Science ®Google Scholar
• Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, . Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging 1999;10:223–32.
   PubMed Web of Science ®Google Scholar
• Fowler A, Forstner D, Lin P, Cuganesan R, Clark J. Multimodality imaging in the radiation treatment planning for a case of carcinoma of the nasopharynx. Acta Oncol 2008; 47:1459–60.
   PubMed Web of Science ®Google Scholar
• Røe K, Muren LP, Rørvik J, Olsen DR, Dahl O, Bakke A, . Dynamic contrast enhanced magnetic resonance imaging of bladder cancer and implications for biological image-adapted radiotherapy. Acta Oncol 2008;47:1257–64.
   PubMed Web of Science ®Google Scholar
• Søvik A, Skogmo HK, Bruland ØS, Olsen DR, Malinen E. DCEMRI monitoring of canine tumors during fractionated radiotherapy. Acta Oncol 2008;47:1249–56.
   PubMed Web of Science ®Google Scholar
• Franiel T, Lüdemann L, Taupitz M, Böhmer D, Beyersdorff D. MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: The feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Radiother Oncol 2009;93: 241–5.
   PubMed Web of Science ®Google Scholar
• Seierstad T, Hole KH, Saelen E, Ree AH, Flatmark K, Malinen E. MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy. Radiother Oncol 2009; 93:279–84.
   PubMed Web of Science ®Google Scholar
• Søvik S, Skogmo HK, Andersen EKF, Bruland ØS, Olsen DR, Malinen E. DCEMRI of spontaneous canine tumors during fractionated radiotherapy: A pharmacokinetic analysis. Radiother Oncol 2009;93:618–24.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R, Breidahl T, Nielsen FU, Maxwell RJ, Stødkiled-Jørgensen H, . Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv Exp Med Biol 2000;476:311–23.
   PubMed Web of Science ®Google Scholar
• Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res 2001;156:503–9.
   PubMed Web of Science ®Google Scholar
• Siemann DW, Warrington KH, Horsman MR. Targeting tumor blood vessels: An adjuvant strategy for radiation therapy. Radiother Oncol 2000;57:5–12.
   PubMed Web of Science ®Google Scholar
• Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys 1980;6:1507–17.
   PubMed Web of Science ®Google Scholar
• Kallman RF, Silini G, Putten LMV. Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors. J Natl Cancer Inst 1967;39:539–49.
   PubMed Web of Science ®Google Scholar
• Fadnes HO, Reed RK, Aukland K. Interstitial fluid pressure in rats measured with a modified wick technique. Microvasc Res 1977;14:27–36.
   PubMed Web of Science ®Google Scholar
• Ley CD, Horsman MR, Kristjansen PEG. Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure. Neoplasia 2007;9:108–12.
   PubMed Web of Science ®Google Scholar
• Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994;271:42–9.
   Web of Science ®Google Scholar
• Gulliksrud K, Brurberg KG, Rofstad EK. Dynamic contrast-enhanced magnetic resonance imaging of tumor interstitial fluid pressure. Radiother Oncol 2009;91:107–13.
   PubMed Web of Science ®Google Scholar
• Kostourou V, Robinson SP, Whitley GSJ, Griffiths JR. Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. Cancer Res 2003;63:4960–6.
   PubMed Web of Science ®Google Scholar
• Sonveaux P. Provascular strategy: Targeting functional adaptations of mature blood vessels in tumors to selectively influence the tumor vascular reactivity and improve cancer treatment. Radiother Oncol 2008;86:300–13.
   PubMed Web of Science ®Google Scholar
• Tozer GM, Prise VE, Lewis G, Xie S, Wilson I, Hill SA. Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses. Clin Cancer Res 2009;15: 3781–90.
   PubMed Web of Science ®Google Scholar
• Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 2002;83:21–38.
   PubMed Web of Science ®Google Scholar
• Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, . A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62: 3408–16.
   PubMed Web of Science ®Google Scholar
• Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, . Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831–42.
   PubMed Web of Science ®Google Scholar
• Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, . Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21:4428–38.
   PubMed Web of Science ®Google Scholar